Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Albireo is a clinical-stage biopharmaceutical company focused on the development a...
Albireo is a clinical-stage biopharmaceutical c...
JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...
JanOne, formerly Appliance Recycling Centers of...
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibi...
Summit Therapeutics is a leader in antibiotic i...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-based biopharmaceutical company focu...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-b...
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing ...
Clearside Biomedical, Inc. is a biopharmaceutic...
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...
Aerie Pharmaceuticals is an ophthalmic pharmace...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
Join the National Investor Network and get the latest information with your interests in mind.